Arbutus Biopharma (ABUS) Assets (2010 - 2026)
Arbutus Biopharma (ABUS) posted Assets of $277.2 million for Q1 2026, up 192.93% sequentially from $94.6 million in Q4 2025, and up 136.87% YoY from $117.0 million in Q1 2025.
Arbutus Biopharma (ABUS) Assets (2010 - 2026) Analysis & Trends
Arbutus Biopharma has reported Assets for 17 years, with the latest figure at $277.2 million in Q1 2026.
- Quarterly Assets rose 136.87% year-over-year to $277.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $277.2 million (up 136.87% YoY) and the FY2025 annual result came in at $94.6 million, down 28.16% from the prior year.
- Assets improved to $277.2 million in Q1 2026 per ABUS's latest filing, from $94.6 million in the prior quarter.
- Over five years, Assets peaked at $277.2 million in Q1 2026 and troughed at $94.6 million in Q4 2025.
- A 5-year average of $164.4 million and a median of $158.6 million in 2023 frame the typical range for Assets.
- The sharpest annual moves came in 2025 and 2026: Assets plunged 35.48% in 2025, then jumped 136.87% in 2026.
- Over 5 years, Assets stood at $195.4 million in 2022, then declined by 26.11% to $144.4 million in 2023, then dropped by 8.79% to $131.7 million in 2024, then fell by 28.16% to $94.6 million in 2025, then jumped by 192.93% to $277.2 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $277.2 million, $94.6 million, and $97.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | 274.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 274.03 Mn |
| Mar 31, 2026 | 277.16 Mn |
| Dec 31, 2025 | 94.62 Mn |
| Sep 30, 2025 | 97.71 Mn |
| Jun 30, 2025 | 103.27 Mn |
| Mar 31, 2025 | 117.01 Mn |
| Dec 31, 2024 | 131.71 Mn |
| Sep 30, 2024 | 140.44 Mn |
| Jun 30, 2024 | 160.04 Mn |
| Mar 31, 2024 | 150.29 Mn |
| Dec 31, 2023 | 144.40 Mn |
| Sep 30, 2023 | 158.64 Mn |
| Jun 30, 2023 | 176.82 Mn |
| Mar 31, 2023 | 191.22 Mn |
| Dec 31, 2022 | 195.42 Mn |
| Sep 30, 2022 | 203.80 Mn |
| Jun 30, 2022 | 215.84 Mn |
| Mar 31, 2022 | 236.88 Mn |
| Dec 31, 2021 | 204.49 Mn |
| Sep 30, 2021 | 165.60 Mn |